Guidance on statin provision in patients without cardiovascular disease is of great practical importance. In recent years, several publications emerged showing conflicting results. The systematic review by Thavendiranathan et al1 is timely and covers a relevant issue but not without limitations. We have 3 observations.
First, this review enrolled moderate- and high-risk patients (average extrapolated 10-year coronary risk, 13%) despite the fact that greater than 80% of the US population who are free of cardiovascular disease do not fall into this risk category.2 No direct conclusions of the effects in this large group can therefore be made. Second, it is unclear how the authors reached the conclusion that “reductions in the risk of major coronary events from statin therapy were significantly associated with greater absolute baseline coronary artery disease risk.”1(p2310) We were unable to reproduce this finding when repeating analyses using the data presented in Tables 1 and 2 in the review by Thavendiranathan et al.1 We constructed a forest plot sorted for increasing baseline risk of the primary studies showing an inverse association (Figure).3- 9 A greater (relative) benefit from statin therapy was significantly associated with smaller absolute baseline risk for major coronary events (P = .04). Third, regarding the number-needed-to-treat analyses,1(p2312) it seems inconsistent that the authors assumed the effects of statins to be constant across risk groups, an assumption contradictory to their metaregression analysis.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Plotted relative risk ratios (95% confidence intervals [CIs]) for major coronary events sorted for baseline risk of primary studies.3- 9 Random effects; heterogeneity χ26= 20.13 (P= .003; I 2= 70.2%).
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
Statin Dosing and LDL Levels
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.